Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib Monotherapy vs Intercalated with Chemotherapy in EGFR-Positive NSCLC
NCT00294762Phase 2Completed
- Sponsor
- OSI Pharmaceuticals
- Start
- Jan 2006
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by OSI Pharmaceuticals. Primary endpoint: 6-month Progression-free Survival. Started Jan 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00294762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00294762.